Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 3,252,494 | 2,211,360 | 4,031,854 | 2,149,155 | 2,574,121 | 14,218,984 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 3,252,494 | 2,211,360 | 4,031,854 | 2,149,155 | 2,574,121 | 14,218,984 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 2,901,301 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 11,317,683 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 3,252,494 | 2,211,360 | 4,031,854 | 2,149,155 | 2,574,121 | 14,218,984 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 6,129 | 63,228 | 69,357 | |||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 177,597 | 15,687 | 239,863 | 148,519 | 92,828 | 674,494 |
| 11 | Total support. Add lines 7 through 10 | 14,962,835 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2024 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2024 |
(iii) Distributable Amount for 2024 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2024 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2024 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2024: | ||||
| a From 2019....... | ||||
| b From 2020....... | ||||
| c From 2021....... | ||||
| d From 2022....... | ||||
| e From 2023....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2024 distributable amount | ||||
|
i
Carryover from 2019 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2024 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2024 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2024, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2024. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2025. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2020..... | ||||
| b Excess from 2021..... | ||||
| c Excess from 2022..... | ||||
| d Excess from 2023..... | ||||
| e Excess from 2024..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: | OTHER INCOME - 2020 AMOUNT: $ 177,597. 2021 AMOUNT: $ 15,687. 2022 AMOUNT: $ 239,863. 2023 AMOUNT: $ 148,519. 2024 AMOUNT: $ 92,828. |
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 4A | BY CONDUCTING THE PROGRAM SERVICES LISTED BELOW, THE JACOBS INSTITUTE HOPES TO CREATE "COLLISIONS" OF IDEAS BETWEEN ACADEMICS, RESEARCHERS AND CLINICIANS TO PROMOTE CLINICAL CARE, ACADEMIC RESEARCH AND ENTREPRENEURIAL ("CARE") EXCELLENCE IN THE TREATMENT OF GLOBAL VASCULAR DISEASE AND RELATED NEUROLOGICAL DISEASES WITH THE ULTIMATE GOAL THAT THESE "COLLISIONS" WILL LEAD TO IMPROVED TREATMENT OF, AND NEW AND IMPROVED TECHNOLOGY AND INNOVATIONS RELATED TO, GLOBAL VASCULAR DISEASE AND RELATED NEUROLOGICAL DISEASES THAT MAY NOT OTHERWISE ATTRACT SUFFICIENT FUNDING IN WESTERN NEW YORK. RESEARCH/ADVANCEMENTS-PROVIDE STAFFING AND RESEARCH SUPPORT TO ACADEMICS, RESEARCHERS AND CLINICIANS AT: (1) THE STATE UNIVERSITY OF NEW YORK, UNIVERSITY AT BUFFALO ("UNIVERSITY AT BUFFALO"), A 501(C)(3) ORGANIZATION; (2) KALEIDA HEALTH (THE LARGEST HOSPITAL NETWORK IN WESTERN NEW YORK), A 501(C)(3) ORGANIZATION; AND (3) OTHER SIMILAR HEALTH-RELATED 501(C)(3) ORGANIZATIONS SELECTED BY THE MANAGEMENT OF THE JACOBS INSTITUTE; IN ORDER TO FACILITATE THE DEVELOPMENT BY SUCH ORGANIZATION OF: (A) ADVANCEMENTS IN THE TREATMENT OF GLOBAL VASCULAR DISEASE AND RELATED NEUROLOGICAL DISEASE; AND (B) CUTTING EDGE TECHNOLOGIES AND OTHER INFORMATION FOR THE IMPROVEMENT OF SUCH TREATMENT. TRAINING AND MEDIA PRODUCTION: ATTRACT, RECRUIT AND RETAIN WORLD CLASS CLINICAL RESEARCH AND ACADEMIC EXPERTS IN THE AREA OF GLOBAL VASCULAR AND NEUROLOGICAL DISEASES. THESE PROGRAMS PROVIDE ADVANCED CLINICAL PHYSICIAN TRAINING SHOWCASING ENDOVASCULAR SIMULATION, BIO SKILLS LABS, CADAVERIC SPECIMENS, ANIMAL MODELS, AND LIVE SURGICAL OBSERVATIONS. THESE FIRST-HAND EXPERIENTIAL TRAINING PROGRAMS ACCOMMODATE UP TO 30 PARTICIPANTS AND ARE BOTH ON-SITE AND VIRTUAL. ENGINEERING SERVICES (PRODUCT DEVELOPMENT, GOOD LABORATORY PRACTICES AND MODEL DESIGN): OFFERS TURNKEY MEDICAL DEVICE DEVELOPMENT SOLUTIONS IN AREAS SUCH AS: PRE-CLINICAL DEVICE TESTING (CADAVERIC, SIMULATION, 3D PRINTED PATIENT-SPECIFIC CUSTOMIZABLE MODELS AND ANIMAL MODELS); PRELIMINARY USER NEEDS AND REQUIREMENT DEVELOPMENT AND VERIFICATION; COMPUTATIONAL RESEARCH, DESIGN AND DEVELOPMENT; AND FAILURE MODE EFFECTS ANALYSIS. IDEA TO REALITY CENTER (I2R) - THE I2R IS FOCUSED ON DEVELOPING NOVEL, SMART-ENGINEERED ENDOVASCULAR MEDICAL DEVICES AT A FASTER PACE AND IN A MORE COST-EFFECTIVE WAY, GETTING THEM TO PATIENTS SOONER. THE I2R CREATES DEVICES DESIGNED BY OR WITH THE PHYSICIANS WHO USE THEM. PHYSICIANS ARE ON-SITE AND AVAILABLE TO I2R ENGINEERS SO THAT OUR ENGINEERING TEAM CAN QUICKLY PROTOTYPE AND VALIDATE POTENTIAL DEVICES. OUR UNIQUE MEDICAL DEVICE DEVELOPMENT MODEL STREAMLINES THE PROOF-OF-CONCEPT PROCESS. CONFERENCES - ARE DEDICATED TO THE PRINCIPLE THAT HONEST OBJECTIVE ASSESSMENT OF FAILURES OF JUDGMENT, EQUIPMENT, AND TECHNIQUE CAN LEAD TO IMPROVED RESULTS IN MEDICAL TREATMENTS. THESE MEETINGS AND SEMINARS SEEK TO IMPROVE PATIENT CARE AND SAFETY, USING FAILURE ANALYSIS, ASSESSMENT OF PROCEDURAL SAFETY AND OTHER QUALITY ASSESSMENT TECHNIQUES. THESE FORUMS ALSO PROVIDE IN DEPTH DISCUSSION IN A PEER-REVIEW CONFIDENTIAL ENVIRONMENT. REGULATORY SERVICES - CONSULTING: CONSULTING SERVICES PROVIDE EXPERTISE IN: (1) STRATEGIC PLANNING AND BUSINESS DEVELOPMENT, (2) MOVING MEDICAL DEVICES TO THE U.S. MARKETPLACE, (3) HELPING DETERMINE THE APPROPRIATE PATHWAY FOR A DEVICE OR DRUG-DEVICE COMBINATION PRODUCT, AND (4) PREPARING FOR A U.S. FOOD AND DRUG ADMINISTRATION SUBMISSION. REGULATORY SERVICES - EARLY FEASIBILITY STUDIES: PROVIDES EXPERTISE ON INITIATING EARLY FEASIBILITY STUDIES IN THE U.S. AND HELP COMPANIES WITH REGULATORY REQUIREMENTS TO ACCELERATE IT ALONG THE PATHWAY TO MARKET, INCLUDING: (1) IDENTIFICATION OF THE RISKS INVOLVED IN BRINGING A MEDICAL DEVICE TO PATIENTS AND IDENTIFYING SOLUTIONS TO MITIGATE THE RISKS TO REGULATORY ENGAGEMENT, (2) EVALUATION OF STRATEGIES AND PROPOSED SUBMISSIONS, AND (3) DRAFTING A SUBSTANTIVE REVIEW OF SUBMISSIONS TO THE FDA. |
| FORM 990, PART VI, SECTION A, LINE 2 | BOARD OF DIRECTORS HAVE BUSINESS RELATIONSHIPS WITH EACH OTHER IN THE NORMAL COURSE OF BUSINESS. |
| FORM 990, PART VI, SECTION B, LINE 11B | DRAFT COPIES OF THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS ARE REVIEWED BY THE JACOBS INSTITUTE'S AUDIT AND COMPLIANCE COMMITTEE. FOLLOWING ITS FINALIZATION, THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS ARE DISTRIBUTED TO THE BOARD OF DIRECTORS. DRAFT COPIES OF THE 990 ARE REVIEWED PRIOR TO ITS FILING BY THE JACOBS INSTITUTE'S BOARD OF DIRECTORS. |
| FORM 990, PART VI, SECTION B, LINE 12C | PRIOR TO THE BOARD OF DIRECTORS ANNUAL MEETING, A MEMORANDUM FROM THE JACOBS INSTITUTE, WHICH INCLUDES THE CONFLICT OF INTEREST POLICY, ALONG WITH A QUESTIONNAIRE, IS DISTRIBUTED TO THE BOARD OF DIRECTORS TO BE FILLED OUT AND COLLECTED BY THE SECRETARY. THE POLICY AND QUESTIONNAIRE ARE ALSO DISTRIBUTED TO JACOBS INSTITUTE EMPLOYEES AT THE SAME TIME, TO BE RETURNED TO THE DIRECTOR OF PEOPLE & OPERATIONS. THE ANSWERS ARE COMPILED AND DISTRIBUTED TO THE BOARD OF DIRECTORS AT THE FOLLOWING BOARD MEETING. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPENSATION OF OFFICERS AND EMPLOYEES ARE REVIEWED BY INDEPENDENT PERSONS, AND FROM TIME TO TIME COMPARABILITY DATA IS USED TO HELP DETERMINE THE APPROPRIATENESS OF PROPOSED COMPENSATION LEVELS. TO DATE, THE PROCESS HAS INCLUDED DISCUSSIONS AMONG SENIOR MANAGEMENT (EXCLUDING ANYONE WITH A POTENTIAL CONFLICT OF INTEREST) FOLLOWED BY A DECISION TO SET COMPENSATION LEVELS. SALARY BENCHMARKING HAS ALSO BEEN USED IN CERTAIN CASES TO ESTABLISH OR SUBSTANTIATE APPROPRIATE SALARY LEVELS. |
| FORM 990, PART VI, SECTION C, LINE 19 | NO DOCUMENTS WERE MADE AVAILABLE TO THE PUBLIC DURING THE TAX YEAR. |
| FORM 990, PART IX, LINE 11G | PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 47,156. MANAGEMENT AND GENERAL EXPENSES 268,254. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 315,410. PAYROLL PROCESSING FEES: PROGRAM SERVICE EXPENSES 28,426. MANAGEMENT AND GENERAL EXPENSES 11,543. FUNDRAISING EXPENSES 1,123. TOTAL EXPENSES 41,092. CONSULTING: PROGRAM SERVICE EXPENSES 1,430,261. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,430,261. |
| Software ID: | |
| Software Version: |